Tradestie Institutional Equity Comparison Engine
RLMD vs VIVS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RLMD Overall Edge
RLMD Captures Institutional Edge (3โ0 Pillars ยท 6โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Relmada Therapeutics, Inc. Common Stock (RLMD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RLMD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, RLMD sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
RLMD N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner
RLMD
Op Margin 0.0% vs -10117.0% ยท YoY +0.0% vs -51.4%
Momentum & Technical Winner
RLMD
1Y -27.2% vs -87.0% ยท 52W Pos 5% vs 5%
Options & Structure Winner
RLMD
BREAKDOWN (36th %ile IV) vs BREAKDOWN (N/A IV)
RLMD
NASDAQ
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.11
+8.93% 1D
Market Cap
$318.5M
1M Return
-3.12%
1Y Return
-27.17%
Forward P/E
N/M
Unified AI Score
45.5 / 100
HOLD
Tech 32.0
Fund 54.0
Flow 68.0
Mom 54.0
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RLMD -27.17%
VIVS -86.99%
Spread: +59.82 pp (RLMD Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RLMD Revenue | VIVS Revenue | RLMD Op. Margin | VIVS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -766.3% | VIVS |
| FY2019 | N/A | $0M | N/A | -882.4% | VIVS |
| FY2020 | N/A | $0M | N/A | -977.9% | VIVS |
| FY2022 | N/A | $0M | N/A | -765.3% | VIVS |
| FY2023 | N/A | $0M | N/A | -4792.2% | VIVS |
| FY2024 | N/A | $0M | N/A | -13840.4% | VIVS |
| FY2025 | N/A | $0M | N/A | -8761.1% | VIVS |
| FY2026 | N/A | $0M | N/A | -8768.7% | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RLMD | VIVS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $318.5M | $2.4M | Larger Scale | RLMD |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -51.4% | Higher Growth | RLMD |
| Operating Margin (TTM) Profitability | 0.0% | -10117.0% | Higher Margin | RLMD |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -64.7% | -343.1% | Higher ROE | RLMD |
| 52-Week Range Position Momentum | 5% ($3โ$8) | 5% ($0โ$3) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 109% Vol | 0.83ฮฒ ยท 480% Vol | Lower Realized Risk | RLMD |
| Unified Institutional Score Composite Signal | 45.5 / 100 (HOLD) | 36.8 / 100 (SELL) | Higher Composite | RLMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RLMD vs VIVS Buy Guide
RLMD
BREAKDOWN
137d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
36th %ile
IV Regime
Balanced (25thโ60th %ile)
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RLMD nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.